Skip to Content

Publications Search - Abstract View

Title: Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
Authors: Castellsagué X,  Naud P,  Chow SN,  Wheeler CM,  Germar MJ,  Lehtinen M,  Paavonen J,  Jaisamrarn U,  Garland SM,  Salmerón J,  Apter D,  Kitchener H,  Teixeira JC,  Skinner SR,  Limson G,  Szarewski A,  Romanowski B,  Aoki FY,  Schwarz TF,  Poppe WA,  Bosch FX,  de Carvalho NS,  Peters K,  Tjalma WA,  Safaeian M,  Raillard A,  Descamps D,  Struyf F,  Dubin G,  Rosillon D,  Baril L
Journal: J Infect Dis
Date: 2014 Aug 15
Branches: IIB
PubMed ID: 24610876
PMC ID: PMC4111909
Abstract: BACKGROUND: We examined risk of newly detected human papillomavirus (HPV) infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment in PATRICIA (Papilloma Trial Against Cancer in Young Adults; NCT00122681). METHODS: Using Poisson regression, we compared risk of newly detected infection and cervical abnormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in the control arm (DNA negative at baseline for the corresponding HPV type [HPV-16: n = 8193; HPV-18: n = 8463]). RESULTS: High titers of naturally acquired HPV-16 antibodies and/or linear trend for increasing antibody levels were significantly associated with lower risk of incident and persistent infection, atypical squamous cells of undetermined significance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater (CIN1+, CIN2+). For HPV-18, although seropositivity was associated with lower risk of ASCUS+ and CIN1+, no association between naturally acquired antibodies and infection was demonstrated. Naturally acquired HPV-16 antibody levels of 371 (95% confidence interval [CI], 242-794), 204 (95% CI, 129-480), and 480 (95% CI, 250-5756) EU/mL were associated with 90% reduction of incident infection, 6-month persistent infection, and ASCUS+, respectively. CONCLUSIONS: Naturally acquired antibodies to HPV-16, and to a lesser extent HPV-18, are associated with some reduced risk of subsequent infection and cervical abnormalities associated with the same HPV type.